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Summary: Patients’ own gut microbiota were the major source of 
K. pneumoniae, but extended-spectrum beta-lactamase strains were acquired 
in the referring hospital. This highlights the potential for rectal screening, and 
the importance of the wider hospital network, for local risk management. 
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Abstract 
 
Background. Klebsiella pneumoniae is a leading cause of extended-
spectrum beta-lactamase (ESBL) producing hospital-associated infections, for 
which elderly patients are at increased risk. 
 
Methods. We conducted a 1-year prospective cohort study, in which a third of 
patients admitted to two geriatric wards in a specialized hospital were 
recruited and screened for carriage of K. pneumoniae by microbiological 
culture. Clinical isolates were monitored via the hospital laboratory. Colonizing 
and clinical isolates were subjected to whole genome sequencing and 
antimicrobial susceptibility testing. 
 
Results. K. pneumoniae throat carriage prevalence was 4.1%, rectal carriage 
10.8% and ESBL carriage 1.7%. K. pneumoniae infection incidence was 
1.2%. The isolates were diverse, and most patients were colonized or infected 
with a unique phylogenetic lineage, with no evidence of transmission in the 
wards. ESBL strains carried blaCTX-M-15 and belonged to clones associated with 
hospital-acquired ESBL infections in other countries (ST29, ST323, ST340). 
One also carried the carbapenemase blaIMP-26. Genomic and epidemiological 
data provided evidence that ESBL strains were acquired in the referring 
hospital. Nanopore sequencing also identified strain-to-strain transmission of 
a blaCTX-M-15 FIBK/FIIK plasmid in the referring hospital. 
 
Conclusions. The data suggest the major source of K. pneumoniae was the 
patient’s own gut microbiome, but ESBL strains were acquired in the referring 
hospital. This highlights the importance of the wider hospital network to 
understanding K. pneumoniae risk and infection control. Rectal screening for 
ESBL organisms upon admission to geriatric wards could help inform patient 
management and infection control in such facilities. 
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Introduction 
Klebsiella pneumoniae is an opportunistic bacterial pathogen associated with 
urinary tract infections (UTIs), pneumonia, septicemia, and wound and soft 
tissue infections in healthcare settings[1]. One of the ESKAPE pathogens that 
are collectively responsible for the majority of hard-to-treat infections in 
hospitalized patients[2] K. pneumoniae is frequently multidrug resistant (MDR; 
defined as resistant to ≥3 classes of antibiotics). Of particular concern are 
isolates that produce extended-spectrum beta-lactamases (ESBLs) or 
carbapenemases, which confer resistance to third generation cephalosporins 
and carbapenems, respectively[2] Among those at risk are infants (who have 
immature immune systems), and the elderly (who have waning immune 
defenses), and both are subject to heightened incidence and severity of 
infections[3]. K. pneumoniae carried asymptomatically in the gastrointestinal 
(GI) tract can disseminate to cause healthcare-associated infections in at-risk 
individuals[4,5], and we recently reported a positive association between 
K. pneumoniae GI carriage and age amongst patients in an intensive care unit 
(ICU)[4]. Older age and hospital stays in geriatric and long term care facilities 
have previously been linked with MDR bacterial colonization and infection[6-
8], hence geriatric hospital patients can be considered an at-risk group for 
carriage and/or infection with K. pneumoniae. Here we aimed to investigate 
the prevalence, diversity and antimicrobial resistance (AMR) of 
K. pneumoniae carried in the GI and respiratory tracts of patients admitted to 
two geriatric care units.  
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Methods 
 
Ethics 
Ethical approval for this study was granted by the Alfred Hospital Ethics 
Committee (Project number #550/12). 
 
Recruitment, Specimen and Data Collection  
Adult patients aged ≥50 years were recruited from two geriatric medicine 
wards at the Caulfield Hospital (CH). Verbal consent to participate was 
required from the patient or an adult responsible for them. Rectal and 
screening swabs were taken at recruitment, usually within the first week of 
admission to the ward. Information on age, sex, dates of hospital and ICU 
admission/s, surgery in the last 30 days, and antibiotic treatment in the last 7 
days were extracted from hospital records. All clinical isolates recovered from 
patients at CH or the referring hospital (Alfred Hospital; AH) patients and 
identified as K. pneumoniae infections by the AH diagnostic laboratory as part 
of routine care were included in the study. See Supplementary Methods for 
further details.  
 
Whole genome sequence analysis 
DNA was extracted and sequenced via Illumina HiSeq. Multi-locus sequence 
typing (MLST) was conducted using SRST2 (v2)[9]. Single nucleotide variants 
(SNVs) were called by aligning reads to a reference genome, and used to 
infer maximum likelihood phylogenetic trees. Phylogenetic lineages were 
defined at a threshold of >0.1% divergence. Draft genome assemblies were 
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constructed using SPAdes (v3.6.1) and used to identify capsule loci with 
Kaptive (v0.4)[10]. Isolates selected for finishing (n=17) were subjected to 
long read sequencing via Oxford Nanopore MinION and hybrid assembly of 
long and short reads using Unicycler (v0.4.0)[11] as described previously[12]. 
All read sets and finished assemblies were deposited in NCBI (accessions in 
Table S1). See Supplementary Methods for full details. 
  
AMR and plasmid analysis 
All clinical and carriage isolates were subjected to antimicrobial susceptibility 
testing using the Vitek2 GNS card and CLSI breakpoints. AMR genes were 
identified from Illumina reads using SRST2 (v0.2.0)[9] to screen against the 
ARG-Annot database[13] (Table S1). The location of AMR genes were 
confirmed by BLAST analysis of finished genome sequences, and the 
Repository of Antibiotic resistance Cassettes (RAC) database and annotation 
service[14]. Plasmid incompatibility types and subtypes were identified using 
PlasmidFinder[15] and established methods for IncC subtyping[16,17]. 
 
Statistical analysis 
All statistical analyses were conducted using R (v3.3.1).  
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Results 
During the one-year study, 296 adults aged ≥50 years and admitted to two 
geriatric wards of CH (30.5% of 973 patients admitted to these wards) were 
screened for K. pneumoniae carriage via rectal and throat swabs. Participant 
characteristics are given in Table 1. Approximately half (n=144, 49%) were 
male and age distributions were similar for both genders, with a median age 
of 84 years (range 55 to 102). Median time of recruitment was day 8 of the 
current hospital admission (range 1– 83 days). Of the 296 patients screened, 
124 (42%) received antimicrobial therapy in the last 7 days, and 34 (11%) 
underwent one or more surgical procedures in the last 30 days (Table 1). 
 
Klebsiella carriage 
Isolates identified as K. pneumoniae were cultured from 13.5% of participants 
(Table 1). We estimate the point prevalence of GI carriage at 10.8% (95% CI, 
7.6–15.1%) and throat carriage at 4.1% (95% CI, 2.2–7.2%). The carriage 
rate was similar among males and females (16% and 11%, respectively; 
p=0.30 using χ2 test). Carriage was not significantly associated with age, sex 
or day of admission in logistic regression models (Table S2), although the 
study was underpowered to investigate this conclusively. GI carriage of ESBL 
K. pneumoniae was detected in five participants (1.7%), four of these isolates 
were also MDR (Table 2).  
 
K. pneumoniae infections 
Twelve (1.2%) CH study ward patients (seven female, five male) were 
diagnosed with K. pneumoniae infections (all UTIs). Patient characteristics are 
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shown in Table 3. The K. pneumoniae UTI rate was very low in non-carriers 
(0.76%, n=2/264), however the numbers are too small for meaningful 
comparisons with the rate in carriers (1/32, 3%; note 9 UTIs occurred in 
patients not screened). Four of the 14 UTI isolates (from 12 patients) were 
MDR, and three produced ESBLs (Table 3).  
 
Genomic diversity of Klebsiella 
We sequenced the genomes of all 59 isolates identified as K. pneumoniae 
from patients in the study wards: 12 from throat swabs, 33 rectal swab 
isolates and 14 UTI isolates, originating from 53 patients. Five carriage isolate 
genomes were excluded from detailed phylogenetic analysis due to sequence 
failure (n=1) or mixed culture (n=4). Genome data from the remaining 54 
isolates confirmed they were members of the K. pneumoniae complex, which 
are typically indistinguishable biochemically[18]: 37 K. pneumoniae, two 
Klebsiella quasipneumoniae, 15 Klebsiella variicola (Figure 1). UTI isolates 
were predominantly K. pneumoniae (n=12/14, 86%). Carriage isolates were 
more diverse with only 63% K. pneumoniae, however the difference was not 
statistically significant (p=0.20 using χ2 test). 
 
A core genome tree of the 54 Klebsiella isolates (Figure 1) showed they 
represent a diverse population comprising 45 phylogenetically distinct 
lineages. These included some common MLST sequence types (STs) 
previously associated with AMR infections in hospitals (ST17, ST20, 
ST340)[19] or severe community-acquired infections (ST23, ST45)[18,20], as 
well as 13 novel STs that were submitted to the MLST database for ST 
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assignment (5 K. pneumoniae and 8 K. variicola). Thirty-seven distinct 
capsule locus types were also detected[10] (Figure 1, Table S1). 
 
Of the four individuals with both rectal and throat isolates, three were 
colonized with different strains at each site (Figure 1). All 
K. quasipneumoniae and K. variicola isolates were singleton strains, i.e. each 
represented a unique lineage detected in a single patient. In contrast, three 
K. pneumoniae lineages were identified in ≥2 patients and thus could 
potentially indicate transmission in CH (ST323, ST29, ST37; dark shading in 
Figure 1). To investigate further, we used long-read sequencing to generate 
high quality, completely resolved genome sequences for these isolates 
(Methods, Table S3), and calculated SNV distances between isolates within 
each cluster (Table 4). The ST37 isolates were separated by 1,816 SNVs 
(433 mutations plus 1,383 SNVs introduced by recombination, Figure S1) and 
thus represent independent strains not linked by recent transmission. The 
ST323 and ST29 isolates were much more closely related (4–40 SNVs), 
consistent with recent transmission. These isolates were ESBL and are 
investigated in detail below. 
 
MDR mechanisms and transmission 
Seven of the 54 isolates were MDR (Figure 1). These belonged to the two 
potential transmission clusters (ST29 and ST323), and UTI and colonizing 
isolates from patient CH0138 (ST340). To investigate the genetic 
mechanisms for resistance, we used long-read sequencing to completely 
resolve these genomes (Methods). The ST29 and ST323 MDR isolates each 
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harboured 4–6 plasmids (Table S3). Notably, all the acquired AMR genes in 
these genomes were localized to the same >200 kbp FIBK/FIIK plasmid 
backbone encoded conjugative transfer functions and shared close similarity 
(>90% coverage and 99% identity) with plasmid pKPN3-307_type A from an 
Italian K. pneumoniae[21]. However there were some differences in the MDR 
regions, resulting in different susceptibility profiles (Figure S2). 
 
Both CH ST29 UTI isolates displayed similar AMR profiles and harboured the 
same set of 12 AMR genes, including the ESBL gene blaCTX-M-15 (Figure S2). 
In one of the ST29 isolates, INF322, the AMR genes were located on a 
243,634 bp circular plasmid (pINF322) carrying the FIBK and FIIK replicons. 
This entire plasmid sequence was integrated into the chromosome of INF249, 
within a 23S rRNA gene (Figure S2A), flanked by copies of IS26 and an 8-bp 
target site duplication (GGCTTTTC). The pINF322 plasmid carried eight 
copies of IS26, and the integration event in INF249 appears to have been 
mediated by the copy situated next to the aac6-Ib gene (Figure S2A). The 
first ST323 carriage isolates, KSB1_4E, carried a plasmid sequence 
(pKSB1_4E) that differed from pINF322 by just 1 SNV. Two of the other three 
ST323 isolates carried the identical plasmid backbone to pKSB1_4E (no 
SNVs). All three harboured blaCTX-M-15 within a variable MDR region (Figure 
S2B). 
 
We investigated transmission of ST29 and ST323 strains and plasmids based 
on SNV counts, phylogenetic relationships and hospital admission data 
(including time in CH and the referring hospital AH). In both the ST29 and 
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ST323 clusters, the data did not support direct transmission between the 
patients in CH, as in many cases they lacked overlapping time in the wards 
(Figure 2A). Given the close genetic distances between isolates (4–40 SNVs, 
Table 4), we hypothesized that they may be linked by transmission in the 
referring hospital rather than CH. To investigate this we analysed all ST29 
and ST323 clinical isolates identified at AH and CH during the study period, 
and constructed core genome phylogenies (Figure 2B). The CH ST29 
isolates belonged to a group of 12 closely related strains (isolated in the last 
four months of the study) that shared a common ancestor with AH isolates, 
from which each differed by 1–4 SNVs (Figure 2B). Similarly the CH ST323 
isolates belonged to a group of 27 strains (isolated throughout the study) that 
shared a common ancestor with AH isolates from which each differed by 
between three (early isolates) and 34 SNVs (late isolates).  
 
All ST29 isolates and n=26/27 ST323 isolates shared the same FIBK/FIIK 
plasmid sequence, separated by ≤1 SNV in the backbone sequence. There 
was variation in the MDR regions resulting in variable AMR phenotypes 
(Figures 2C, S2C), but blaCTX-M-15 was retained in all but two isolates.  
 
Carbapenem resistance 
Meropenem resistant K. pneumoniae was detected in one CH patient 
(CH0138). Their rectal carriage isolate and two clinical urine isolates, 
collected on the same day, shared near-identical chromosomal sequences 
separated by a single SNV (Figure 3). Patient CH0138 was discharged after 
two months and re-admitted to AH nearly two months later. K. pneumoniae 
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was isolated from clinical urine samples on days four and ten of the second 
admission. These were also ST340, separated from the earlier isolates by 3–5 
SNVs (Figure 3). 
 
Two distinct AMR patterns were observed amongst the CH0138 isolates: all 
were ESBL and MDR, however the first and last urine isolates were 
additionally resistant to cefoxitin, cefepime and meropenem (Figure 3A). 
Completion of the genomes with long reads showed the MDR phenotypes 
were conferred by (a) chromosomal insertions of sul1, aadA2 (via a type 1 
integron) and blaCTX-M-15 (via ISEcp1); (b) two large conjugative plasmids: a 
novel 90 kbp plasmid sharing two replicon genes (repB and repE) with pK245 
(accession DQ449578), carrying aac3-IIa, aac6Ib-cr, catB4, strAB, blaOXA-1, 
sul2 and qnrB1; and (c) an IncC type 2 plasmid[16] (also known as IncA/C2 
plasmid sequence type 3[17]) carrying blaTEM, aadA2, tetA, dfrA14 (Figure 
3C, Table S4). In the meropenem-resistant strains, the IncC plasmid also 
carried the carbapenemase blaIMP-26 as well as mphA, aac3-IIa and catB3 
(Figure 3C).  
 
Comparison to clinical isolates identified in AH during the study period 
identified four additional ST340 isolates from two patients, which shared the 
same plasmids and chromosomal AMR determinants and were separated 
from the first CH0138 isolate by 2–5 chromosomal SNVs (Figure 3A, Table 
S4). Three strains (blood, CSF and rectal swab) were isolated from patient 
AH0095 on admission to ICU with sepsis. This followed a month-long stay in 
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AH, which overlapped with the AH admissions of the other two patients, likely 
providing the opportunity for transmission (Figure 3B). 
 
 
Discussion 
We estimated overall carriage prevalence in the first week of admission to the 
geriatric unit at 13.5%, with 10.8% GI carriage and 4% throat carriage. GI 
carriage prevalence was significantly higher than we estimated previously for 
patients admitted to the AH ICU with no recent healthcare exposure[4] (5.9%, 
OR 1.94 [95% CI, 1.0–3.7], p=0.03) but significantly lower than that for ICU 
patients who had been in hospital for >2 days or had recent surgery (19%, OR 
0.52 [0.3–0.9], p=0.02). The rate was also lower than that recently estimated 
for ICU and hematology/oncology patients at a US hospital[5] (23%, OR 0.41 
[0.27–0.60], p=7x10-7).  
 
Colonizing isolates were diverse (Figure 1) and mostly unique to individual 
participants, consistent with our earlier observations in ICU patients[4] and the 
recent US study[5]. Hence in most cases, these strains likely represent 
established members of the patients’ microbiota rather than hospital-acquired 
bacteria. In the ICU, K. pneumoniae carriage is significantly associated with 
subsequent infection (OR ≥4)[4,5]. In the current setting, K. pneumoniae 
infections occurred at a similar rate (1.2% vs 1.8–2.2%, p>0.1) but the 
number of cases was too small to explore the link between colonization and 
infection directly. Notably the 12 patients with K. pneumoniae infections were 
infected with 11 different lineages, consistent with most patients developing a 
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UTI from their own microbiota. The exceptions were two UTIs associated with 
ESBL ST29, acquired by both patients in the referring hospital (Figure 2). 
 
ESBL carriage (1.7%) was much rarer than previously reported in point 
prevalence studies of geriatric units or long term care facilities[22,23]. This is 
unsurprising as we aimed to screen patients during the first week of their CH 
stay and only focused on K. pneumoniae. The MDR strains identified at CH all 
belonged to lineages that have been previously associated with hospital 
outbreaks of ESBL and/or carbapenemase producing (CP) K. pneumoniae on 
other continents (ST29, ST323, ST340)[24],[25], indicating the emergence of 
globally distributed ESBL strains in Australia. The spread of internationally 
common ST258 strains harbouring the K. pneumoniae carbapenemase 
(KPC), which are common internationally, have also been recently detected in 
Australia[26]. FIBK/FIIK plasmids are frequently reported as disseminators of 
blaCTX-M-15 and other AMR genes in K. pneumoniae, E. coli and other enteric 
bacteria isolated from humans, animals and the environment[27,28]. The IncC 
plasmid carrying blaIMP was recently reported in K. pneumoniae (ST unknown) 
isolated from Australian wild birds[29], indicating that this plasmid and 
possibly the host strain are involved in spreading carbapenemases between 
animals and humans. 
 
This study employed Illumina short-read WGS to identify high-confidence 
SNVs with which to identify lineages and AMR genes, bolstered by long-read 
sequencing to resolve plasmids and AMR gene context and to maximize 
resolution for detecting transmission. While this strategy has been used in 
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other studies[30-33] , ours is the first to adopt multiplex nanopore sequencing 
and hybrid assembly to rapidly and cost-efficiently complete genome 
sequences of interest in a high-throughput manner[11,12] (Tables S3, S4). 
However, unravelling the source of MDR K. pneumoniae in CH also required 
exploring patient movement prior to CH admission, and phylogenetic context 
provided by additional isolates from the referring hospital. 
 
Our analyses revealed that all MDR K. pneumoniae isolated at CH were 
linked to transmission clusters at the referring hospital (Figures 2-3). This 
suggests that MDR carriage is rare in the community, but MDR ESBL 
K. pneumoniae were occasionally acquired in the referring hospital prior to 
transfer to CH (ESBL GI carriage prevalence 1.7%, ESBL infection incidence 
0.31%). These findings are likely generalisable to other hospital referral 
networks and highlight the benefits of exploring transmission at a multi-facility 
level[34,35]. However, larger studies will be needed to confirm the importance 
of referral networks for transmission of ESBL organisms, as has been 
demonstrated for MRSA and Clostridium difficile[34,35] , and to explore 
specific risk factors and the relevance to healthcare-associated infections.  
 
It is noteworthy that the two ESBL lineages transmitting at AH (ST323 and 
ST29) shared the same FIIK/FIBK blaCTX-M-15 plasmid. Given that ST323 
appears to have been circulating at AH for months prior to the common 
ancestor of the ST29 strains, we hypothesise that the plasmid transferred 
from ST323 to ST29 within the hospital, promoting transmission of ST29 
within AH. This highlights the importance of tracking ESBL or CP plasmids as 
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well as their host strains, as has been noted previously[30,31,36] 
 
The spread of CP K. pneumoniae within the referring hospital is concerning. 
The CP ST340 strain carrying blaIMP and blaCTX-M-15 was identified in clinical 
isolates from two patients, and additional variants lacking blaIMP were found in 
one of these patients plus a ST340 UTI isolate from a third patient (Figure 3). 
Notably the ST340 strain was detected on rectal swabs from both patients 
who were screened for carriage (one CH patient in the present study; one ICU 
patient in the prior study[4]). However, it is encouraging to note that we 
detected no evidence of its transmission within the CH wards.  
 
Only one third of patients were recruited for GI carriage screening at CH. 
While two of the three patients with MDR infections were not screened, given 
the strong evidence that they acquired their infecting strain (ESBL ST29) in 
the referring hospital (Figure 2) it is likely that they would have been detected 
as ESBL carriers if they had been swabbed on arrival. Surveillance swabs are 
frequently recommended to screen for carriage of MDR organisms in a variety 
of settings[37-39], but their role in the management of ESBL or CP Gram 
negative infections outside of outbreaks remains controversial[40]. Our study 
suggests that screening upon transfer from tertiary referral hospitals to 
specialized hospitals could be valuable for management or prevention of MDR 
infections. 
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Tables 
 
Table 1. Characteristics of participants screened for K. pneumoniae 
carriage. Timing is indicated in days of the current admission to hospital (day 
of admission = day 1). ‘Recent antibiotics’ indicates antimicrobial therapy in 
the last 7 days prior to screening; ‘Recent surgery’ indicates surgical 
procedures of any kind in the last 30 days.  
 
 Total Male Female 
Number screened 296 144 (49%) 152 (51%) 
Age  
  Median 86 85 86 
  Range 55 – 102 55 – 97 58 – 102 
Timing of baseline swab (day of current hospital admission) 
  Median 8 7 9 
  Range 1 – 83 1 – 69 1 – 83 
Recent antibiotics 123 (42%) 59 (41%) 64 (42%) 
Recent surgery 34 (11%) 15 (10%) 19 (12%) 
K. pneumoniae positive culture 
  Rectal swab 32 (10.8%) 19 (59%) 13 (41%) 
  Throat swab 12 (4.1%) 7 (58%) 5 (42%) 
  Both 4 (1.4%) 3 (75%) 1 (25%) 
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Table 2. Details of participants with rectal screening swabs positive for 
ESBL K. pneumoniae. CH0031 isolate carried blaCTX-M-55; the others carried 
blaCTX-M-15.  ‘Recent antibiotics’ indicates antibiotic treatment in the last 7 days 
prior to screening; ‘Recent surgery’ indicates surgery of any kind in the last 30 
days. AMR phenotyping was conducted using Vitek2 and interpreted using 
CLSI thresholds, drugs to which resistance was detected are listed as follows: 
Amp, Ampicillin; Amc, Amoxicillin-clavulanic acid; Tim, Ticarcillin-clavulanic 
acid; Tzp, Tazobactam-piperacillin; Kz, Cefazolin; Fox, Cefoxitin; Caz, 
Ceftazidime; Cfx, Cefuroxime; Cro, Ceftriaxone; Gen, Gentamicin; Tob, 
Tobramycin; Cip, Ciprofloxacin; Nor, Norfloxacin; Tmp, Trimethoprim; Sxt, 
Trimethoprim-sulfamethoxazole; Van, vancomycin. All four isolates were 
susceptible to cefepime, meropenem and amikacin. 
 
Patient Age  Sex Recent 
surgery 
Recent 
antibiotics 
Antimicrobials to which 
resistance was detected 
CH0031 96 M no Cro Amp, Kz, Cro 
CH0138 91 F yes Tmp Amp, Amc, Tim, Tzp, Kz, Caz, 
Cro, Gen, Tob, Cip, Nor, Tmp, Sxt 
CH0142 72 M no - Amp, Tim, Tzp, Kz, Fox, Caz, Cro, 
Tob, Cip, Tmp, Sxt 
CH0260 72 F no Amc Amp, Kz, Cro, Tmp, Sxt 
CH0274 73 F no Van, Cip, Cfx Kz, Cro, Tmp, Sxt 
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Table 3. Details of K. pneumoniae infections (UTI). Characteristics of 
patients and corresponding urine isolates are provided. Carriage screening 
swab results are given for patients who were also recruited as participants in 
the carriage study (NP, not participating). AMR phenotyping was conducted 
using Vitek2 and interpreted using CLSI thresholds, drugs displaying 
resistance are listed using the following key: Amp, Ampicillin; Amc, 
Amoxicillin-clavulanic acid; Tim, Ticarcillin-clavulanic acid; Tzp, Tazobactam-
piperacillin; Kz, Cefazolin; Fox, Cefoxitin; Caz, Ceftazidime; Cro, Ceftriaxone; 
Fep, Cefepime; Mer, Meropenem; Ami, Amikacin; Gen, Gentamicin; Tob, 
Tobramycin; Cip, Ciprofloxacin; Nor, Norfloxacin; Tmp, Trimethoprim; Sxt, 
Trimethoprim-sulfamethoxazole. Where two clinical isolates were cultured, 
these are labelled 1 and 2, and AMR phenotypes are given for both. *=Isolate 
identified from genome data as K. variicola; **=Isolate identified as ESBL 
producer. 
 
Patient Age  Sex 
Carriage 
positive  
Antimicrobials to which clinical isolate/s 
displayed resistance 
CH0110 92 F no 1: Amp 
2: Amp, Tmp and Sxt 
CH0138 91 F yes  
(rectal 
swab) 
1: Amp, Amc, Tim, Tzp, Kz, Caz, Cro**, Gen, 
Tob, Cip, Nor, Tmp, Sxt 
2: Amp, Amc, Tim, Tzp, Kz, Caz, Cro**, Gen, 
Tob, Cip, Nor, Tmp, Sxt, Fox, Fep, Mer 
CH0258 91 F no Amp, Amc, Tim, Kz, Caz, Cro**, Tob, Tmp, Sxt 
KC0049 78 F NP Amp 
KC0061 90 F NP Amp 
KC0109 69 M NP Amp 
KC0135 88 F NP Amp* 
KC0136 90 F NP Amp* 
KC0191 91 M NP Amp, Amc, Tim, Tzp, Kz, Cro**, Fep, Tob, 
Tmp, Sxt 
KC0216 86 M NP Amp, Nor 
KC0302 81 M NP Amp 
KC0303 71 M NP Amp 
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Table 4. Pairwise genetic differences between isolates in multi-patient 
lineages. Each isolate within a lineage is listed with accompanying patient 
and sample data, as well as the number of chromosomal and plasmid SNVs 
detected between the isolate and the first collected isolate from the same 
lineage. *In INF249, the FIBK/FIIK plasmid sequence is integrated into the 
chromosome. NA, no FIBK/FIIK sequence detected. 
 
Patient 
ID Age Sex Sample ID Specimen 
Sample 
date 
SNVs 
Chromosome FIBK/FIIK plasmid 
ST29  
KC0191 91 M INF249 UTI 01/12/2013 - - 
CH0258 91 F INF322 UTI 17/02/2014 4 39* 
ST323  
CH0142 72 M KSB1_4E Rectal  10/09/2013 - - 
CH0150 85 M KSB1_7E Rectal  17/09/2013 4 NA 
CH0260 72 F KSB1_10J Rectal  11/02/2014 19 0 
CH0274 73 F KSB2_1B Rectal  25/02/2014 40 5 
ST37 (KL14) 
CH0110 92 F INF042 UTI 08/05/2013 - - 
CH0110 92 F INF059 UTI 16/05/2013 4 NA 
CH0252 85 M KSB1_7J Rectal  04/02/2014 1,786 NA 
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Figure Legends 
 
Figure 1.  Core genome phylogeny for Klebsiella isolated from patients 
in the study wards, indicating MLST and capsule locus (KL) genotypes, 
and antimicrobial resistance (AMR) phenotypes. Tree is a maximum 
likelihood phylogeny inferred from 489,069 SNPs in 3,769 core genes; all 
branches defining species or lineages (i.e. clades of isolates sharing MLST 
sequence types) have >90% bootstrap support. Scale bar indicates nucleotide 
divergence. Clusters of genomes with patristic distance ≤0.1% nucleotide 
divergence are highlighted. Curved lines indicate isolates from the same 
patient (green, carriage isolates only; pink, infection isolates). K loci were 
identified using Kaptive. AMR phenotypes, determined using Vitek2 and 
interpreted according to CLSI guidelines, are indicated in the heatmap and 
coloured by drug class according to inset legend; *=multidrug resistance 
(resistant to ≥3 drug classes). Amp, Ampicillin; Amc, Amoxicillin-clavulanic 
acid; Tim, Ticarcillin-clavulanic acid; Tzp, Tazobactam-piperacillin; Kz, 
Cefazolin; Fox, Cefoxitin; Caz, Ceftazidime; Cro, Ceftriaxone; Fep, Cefepime; 
Mer, Meropenem; Ami, Amikacin; Gen, Gentamicin; Tob, Tobramycin; Cip, 
Ciprofloxacin; Nor, Norfloxacin; Tmp, Trimethoprim; Sxt, Trimethoprim-
sulfamethoxazole.  
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Figure 2. Multidrug resistant ESBL lineages associated with multiple 
patients in the study wards. (A) Timelines for Caulfield and Alfred Hospital 
stays for patients in the Caulfield Hospital study wards who were infected with 
ST29 or colonized with ST323 K. pneumoniae. (Note ST340 data is shown 
separately in Figure 3.) Details of all admissions to the Caulfield Hospital 
(study site) or the Alfred Hospital (referring hospital) during the one-year study 
period (April 1, 2013 – March 31, 2014) were extracted from the hospital 
records of these patients. (B) Midpoint-rooted core genome phylogenetic 
trees for all ST29 and ST323 K. pneumoniae isolated at Caulfield or Alfred 
Hospitals during the study period. Tips are coloured by hospital of 
corresponding specimen collection, according to inset legend. Isolates from 
the Caulfield Hospital study wards are highlighted in grey. Branches are 
labelled with the number of chromosomal SNVs defining the branch (black 
numbers, above branch) and the number of SNVs in the corresponding 
FIBK/FIIK plasmid sequence, relative to the major genotype (red numbers, 
below branch, see Figure S2 for plasmid tree; =plasmid lost; chr=plasmid 
integrated into chromosome). Antimicrobial resistance (AMR) phenotypes, 
determined using Vitek2 and interpreted according to CLSI guidelines, are 
indicated in the heatmap and coloured by drug class according to inset 
legend. Amp, Ampicillin; Amc, Amoxicillin-clavulanic acid; Tim, Ticarcillin-
clavulanic acid; Tzp, Tazobactam-piperacillin; Kz, Cefazolin; Fox, Cefoxitin; 
Caz, Ceftazidime; Cro, Ceftriaxone; Fep, Cefepime; Mer, Meropenem; Ami, 
Amikacin; Gen, Gentamicin; Tob, Tobramycin; Cip, Ciprofloxacin; Nor, 
Norfloxacin; Tmp, Trimethoprim; Sxt, Trimethoprim-sulfamethoxazole.  
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Figure 3. Carbapenemase lineage ST340. (A) Core genome phylogenetic 
tree of all ST340 isolates identified at Caulfield or Alfred Hospitals during the 
study period. Branches are labelled with number of chromosomal SNVs. CSF, 
cerebral spinal fluid. Antimicrobial resistance (AMR) phenotypes, determined 
using Vitek2 and interpreted according to CLSI guidelines, are indicated in the 
heatmap and coloured by drug class according to inset legend. Amp, 
Ampicillin; Amc, Amoxicillin-clavulanic acid; Tim, Ticarcillin-clavulanic acid; 
Tzp, Tazobactam-piperacillin; Kz, Cefazolin; Fox, Cefoxitin; Caz, Ceftazidime; 
Cro, Ceftriaxone; Fep, Cefepime; Mer, Meropenem; Ami, Amikacin; Gen, 
Gentamicin; Tob, Tobramycin; Cip, Ciprofloxacin; Nor, Norfloxacin; Tmp, 
Trimethoprim; Sxt, Trimethoprim-sulfamethoxazole. (B) Timelines for hospital 
stays; all admissions to the Caulfield Hospital (where the study wards were 
located) or the Alfred Hospital (referring hospital) during the 1-year study 
period (April 1, 2013 – March 31, 2014) were extracted from hospital records 
of these patients. (C) Comparison of AMR regions in the two forms of IncC 
plasmid identified in these isolates; AMR and transposase genes are labelled 
and coloured according to the inset legend. CP=carbapenemase producing, 
defined by presence of blaIMP-4 gene and phenotypic meropenem resistance 
(Mer in panel A). 
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Beta-lactamases   Aminoglycoside resistance  Chloramphenicol resistance Other mobility genes
ESBLs    Fluoroquinolone resistance  Macrolide resistance  Transposon/integron
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